Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 5:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2377–2400 of 85,906 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 1 Clear all

Conditions: Lower Urinary Tract Symptoms, Overactive Bladder
Interventions: Urodynamics + TETRA - NIRS; Device
Lead sponsor: Laborie Medical Technologies Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Benign Prostatic Hyperplasia
Interventions: NX-1207; Drug
Lead sponsor: Nymox Corporation; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 28
States / cities: Huntsville, Alabama • Atherton, California • San Diego, California + 25 more

Conditions: Adenomatous Polyposis Coli
Interventions: Erlotinib, Sulindac, Placebo A, Placebo B; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 69 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: NAD, NAD+ Levels in the Blood
Interventions: Qualia NAD⁺ version 1, Qualia NAD⁺ version 2, Qualia NAD⁺ version 3, Placebo; Dietary Supplement
Lead sponsor: Qualia Life Sciences; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Carlsbad, California

Conditions: Healthy
Interventions: azelaic acid pre-foam formulation, Vehicle pre-foam formulation, Water, Sodium lauryl sulfate; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Sleep
Interventions: Fruit/Honey drink, Placebo; Dietary Supplement
Lead sponsor: Mayo Clinic; Other
Eligibility: 60 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Muscular Atrophy, Spinal
Interventions: risdiplam, omeprazole; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 131 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Daytona Beach, Florida • Springfield, Missouri • Dallas, Texas + 1 more

Conditions: Ulcerative Colitis
Interventions: Ontamalimab, Placebo; Drug · Other
Lead sponsor: Shire; Industry
Eligibility: 16 Years to 81 Years
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 94
States / cities: Mesa, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 80 more

Conditions: Carpal Tunnel Syndrome, Patient Satisfaction
Interventions: Educational Videos; Other
Lead sponsor: Carilion Clinic; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions: Birinapant, Carboplatin, Laboratory Biomarker Analysis, Pharmacological Study; Drug · Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Hairy Cell Leukemia, Multiple Myeloma
Interventions: LMY-922; Biological
Lead sponsor: Luminary Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Breast Cancer
Interventions: Paclitaxel, Docetaxel, Capecitabine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Female only
Enrollment: 603 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Neurofibromatosis 1, Neurofibromatosis 2, Schwannomatosis, NF2-related Schwannomatosis
Interventions: Not listed
Lead sponsor: The Children's Tumor Foundation; Other
Eligibility: Not listed
Enrollment: 20,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2050
U.S. locations: 1
States / cities: New York, New York

Conditions: GYN Disorders
Interventions: Group 1: Nella VuSleeve, Group 2: Nella NuSpec, Group 3: NellaSpec, Group 4: Nella Insert; Device
Lead sponsor: Ceek Enterprises; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 154 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Colorectal Cancer
Interventions: Mailed FIT Outreach, Standardized navigation; Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 50 Years to 75 Years
Enrollment: 55,999 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Alcohol Use Disorder
Interventions: Suvorexant 10 mg, Placebo; Drug · Other
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Myofascial Pain, Myofascial Trigger Point Pain
Interventions: 1% plain lidocaine and 0.25% plain bupivacaine; Combination Product
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Alopecia Areata
Interventions: PF-06651600 Induction Dose, PF-06651600 Maintenance Dose #1, PF-06651600 Maintenance Dose #2, PF-06651600 Maintenance Dose #3, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 718 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 46
States / cities: Birmingham, Alabama • Beverly Hills, California • Irvine, California + 25 more

Conditions: Cocaine Dependence
Interventions: Buprenorphine + Naltrexone, Placebo + Naltrexone; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 65 Years
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 11
States / cities: Los Angeles, California • San Francisco, California • Denver, Colorado + 8 more

Conditions: Astrocytoma, Glioblastoma, Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma, Recurrent Glioblastoma
Interventions: Mycophenolate Mofetil, Quality-of-Life Assessment, Radiation Therapy, Temozolomide; Drug · Other · Radiation
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 3
States / cities: Chicago, Illinois • Lake Forest, Illinois • Warrenville, Illinois

Conditions: Dry Eye Syndromes
Interventions: Ecabet 2.83%, Ecabet 3.70%, Vehicle; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 3
States / cities: Lewiston, Maine • Andover, Massachusetts • Dover, New Hampshire

Conditions: Ischemic Central Retinal Vein Occlusion
Interventions: Ranibizumab (Lucentis); Drug
Lead sponsor: Greater Houston Retina Research; Other
Eligibility: 19 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Dry Eye Syndrome
Interventions: Rebamipide 2% ophthalmic suspension, Placebo (vehicle); Drug
Lead sponsor: Kubota Vision Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 564 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 34
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Artesia, California + 31 more

Conditions: Healthy Volunteers
Interventions: LOXO-305, Itraconazole, Rifampin; Drug
Lead sponsor: Loxo Oncology, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Daytona Beach, Florida

Search by objective public record fields.

Tetra-NIRS Clinical Study

Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)

A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients

Comparison of Three Qualia NAD⁺ Formulations on Intracellular NAD⁺ Levels

21 Day Irritancy Test of Azelaic Acid Pre-foam Formulation

Addressing Sleep Problems in Older Adults

Bioavailability and Bioequivalence of Two Risdiplam Tablets in Healthy Participants

An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis

Postoperative Care After Carpal Tunnel Release Using Short Educational Videos

Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC)

BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies

Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer

The NF Registry Sponsored by the Children's Tumor Foundation

Evaluation of the Nella Women's Care Line

ColoRectal Cancer Screening for Southern California Community Health Centers

Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking

Investigating the Minimum Number of Needling Required to Optimize Trigger Point Injections Outcome

PF-06651600 for the Treatment of Alopecia Areata

Cocaine Use Reduction With Buprenorphine

Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma

Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome

Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion

Efficacy and Safety of Rebamipide in Subjects With Dry Eye Syndrome

Study of the Effects of Itraconazole and Rifampin on LOXO-305 in Healthy Participants